Axolabs is headquartered in Kulmbach, Germany. The company is an independent, privately held limited liability corporation (GmbH).


The majority of research groups in the field of nucleic acid and oligonucleotide-based therapeutics worldwide belongs to our clients, including >12 Big Pharma enterprises, >150 Biotech companies, >30 academic research institutes and Venture Capital firms. Moreover, we have collaborations with academic partners relating to own publically funded research projects.


Historically, the company was started under the name of Ribopharma AG in 2000 as the first company in the world to focus on RNAi therapeutics. In 2003 Ribopharma AG merged with Alnylam Pharmaceuticals Inc. to create the leading RNAi therapeutics company. In 2007 – in frame of a spin-off from Alnylam Europe AG – Roche Kulmbach GmbH was established as Roche's Center of Excellence for RNA Therapeutics and focused on the discovery of novel therapeutics based on oligonucleotides. In November 2011 the management bought out the assets from Roche Kulmbach GmbH and established Axolabs GmbH.